This trial is testing a new lung cancer treatment that combines a immunotherapy drug with radiation. The radiation is given on a different schedule than usual, either every other day or every four weeks. The trial will last for two years and follow patients closely to see how well the treatment works.
- Non-Small Cell Lung Cancer
2 Primary · 7 Secondary · Reporting Duration: 3 years
Awards & Highlights
2 Treatment Groups
Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm
1 of 2
Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalum...
1 of 2
52 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic radiation therapy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment for this investigation open at the present?
"According to the details present on clinicaltrials.gov, enrollment for this trial is still open. After being initially posted August 10th 2021 and subsequently edited February 23rd 2022, patients are now eligible to apply." - Anonymous Online Contributor
What is the major goal of this examination?
"This medical trial is designed to assess the Quality of Life (QoL) improvements following treatment. Secondary outcomes include Overall Response Rate, Progression Free Survival, and Out-of-Field Control which will be evaluated during a two year post-treatment period using Kaplan Meier methodologies." - Anonymous Online Contributor
What is the aggregate amount of participants involved in this investigation?
"Affirmative. The clinical trial registry hosted on clinicaltrials.gov verifies that this medical study is actively recruiting participants, having first been posted on August 10th 2021 and last updated February 23rd 2022. At present, the research team needs to recruit 52 patients from a single site." - Anonymous Online Contributor
Has there been precedent for employing Stereotactic radiation therapy in scientific research?
"Presently, there are 333 investigations of Stereotactic radiation therapy in progress. Of these studies, 52 have reached Phase 3. Notably, Cordoba, Texas is the primary site for this research; however a total of 12937 centres are running trials related to this method of treatment." - Anonymous Online Contributor
Has the FDA given its stamp of approval to Stereotactic radiation therapy?
"Clinical data has provided a fair degree of assurance regarding the safety profile of Stereotactic Radiation Therapy, thus awarding it a score of 2. However, there is no existing data that confirms its efficacy as this trial is only in Phase 2." - Anonymous Online Contributor
For what medical concerns is Stereotactic radiation therapy commonly employed?
"Stereotactic radiation therapy is frequently utilized to treat unresectable stage III non-small cell lung cancer. Moreover, it can be employed in treating advanced directives and metastatic ureteral urothelial carcinoma that has not been previously addressed." - Anonymous Online Contributor